KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) Operating Margin (2017 - 2026)

Twist Bioscience has reported Operating Margin over the past 10 years, most recently at 41.42% for Q1 2026.

  • Quarterly Operating Margin rose 336.0% to 41.42% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 33.9% through Mar 2026, up 2396.0% year-over-year, with the annual reading at 36.18% for FY2025, 3437.0% up from the prior year.
  • Operating Margin was 41.42% for Q1 2026 at Twist Bioscience, down from 31.73% in the prior quarter.
  • Over five years, Operating Margin peaked at 30.23% in Q3 2025 and troughed at 126.34% in Q1 2022.
  • The 5-year median for Operating Margin is 65.7% (2023), against an average of 70.02%.
  • Year-over-year, Operating Margin plummeted -1380bps in 2024 and then soared 7780bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 82.28% in 2022, then rose by 20bps to 65.7% in 2023, then surged by 41bps to 39.05% in 2024, then rose by 19bps to 31.73% in 2025, then crashed by -31bps to 41.42% in 2026.
  • Per Business Quant, the three most recent readings for TWST's Operating Margin are 41.42% (Q1 2026), 31.73% (Q4 2025), and 30.23% (Q3 2025).